Post-daunorubicin treatment effects on cardiovascular function in the Ts65Dn mouse model of Down syndrome
Michelle A. Buckman, Anastasiia Vasileva, Hardik Kalra, Immaculate Edwin, Guiru Ma, Mikhail Vasilyev, Barry London, Charles R. Jedlicka, Gary Beasley, Patrick John Breheny, Michael H. Tomasson, Melissa Lowe Bates
This study examines the chronic cardiovascular effects of daunorubicin in Ts65Dn mice, a model of Down syndrome, compared to wild-type mice, finding strain-specific differences in cardiac and vascular function.
Physiology · May 1, 2026Peer-reviewedCancer Biology